Login to Your Account

Affymax Series D Garners $60M To Boost Hematide

By Randall Osborne

Tuesday, July 19, 2005
Affymax Inc. raised $60 million in a Series D financing to push along its Phase II candidate Hematide for anemia, which is expected to be studied in four separate trials by late fall. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription